CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
603122 Cowealth Medical China
- 6.49
- -0.04-0.61%
Market Closed Apr 30 15:00 CST
2.58BMarket Cap180.28P/E (TTM)
6.58High6.47Low48.64KlotVolume6.48Open6.53Pre Close31.70MTurnover1.22%Turnover Ratio94.06P/E (Static)398.05MShares8.7952wk High2.22P/B2.58BFloat Cap4.7152wk Low7.18Limit Up398.05MShs Float26.88Historical High5.88Limit Down1.69%Amplitude4.64Historical Low0.06Dividend TTM6.52Avg Price27.77KlotAsk0.92%Div YieldTTM100Lot Size19.84KlotBid
Cowealth Medical China Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -34.75%179.24M | -14.09%1.07B | -15.62%789.7M | -11.13%525.96M | 8.49%274.67M | -0.39%1.25B | 18.64%935.88M | 18.54%591.84M | -3.68%253.17M | -5.19%1.26B |
| Refunds of taxes and levies | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.22M |
| Cash received relating to other operating activities | 64.82%3.39M | -34.54%16.87M | 170.24%34.58M | 280.93%21.26M | 39.51%2.05M | 32.01%25.78M | 85.33%12.8M | 57.25%5.58M | -18.73%1.47M | -14.12%19.53M |
| Cash inflows from operating activities | -34.01%182.62M | -14.50%1.09B | -13.11%824.29M | -8.40%547.23M | 8.67%276.72M | 0.01%1.28B | 19.22%948.68M | 18.81%597.43M | -3.78%254.64M | -5.25%1.28B |
| Goods services cash paid | -65.81%91.21M | -25.99%767.26M | -17.83%668.98M | -14.91%462.51M | -12.70%266.74M | -5.73%1.04B | 0.88%814.11M | 15.31%543.55M | 19.64%305.54M | -3.84%1.1B |
| Staff behalf paid | -16.64%28.45M | -4.72%108.15M | 7.93%88.56M | -3.79%61.7M | -4.81%34.13M | 7.93%113.51M | -0.56%82.06M | 6.87%64.13M | 3.46%35.85M | 18.60%105.17M |
| All taxes paid | -12.97%10.95M | -33.34%37.13M | -36.13%30.44M | -24.13%22.64M | -5.28%12.58M | -12.39%55.71M | -16.92%47.66M | -10.89%29.83M | -46.42%13.28M | -3.89%63.58M |
| Cash paid relating to other operating activities | -15.41%13.52M | -22.26%45.67M | -33.40%38.85M | -31.41%23.77M | 14.55%15.98M | 55.74%58.75M | 59.89%58.34M | 32.95%34.65M | -17.29%13.95M | -8.07%37.72M |
| Cash outflows from operating activities | -56.25%144.13M | -24.23%958.21M | -17.49%826.83M | -15.11%570.62M | -10.63%329.44M | -3.18%1.26B | 1.91%1B | 13.75%672.16M | 11.13%368.63M | -2.49%1.31B |
| Net cash flows from operating activities | 173.02%38.49M | 1,076.77%132.75M | 95.23%-2.55M | 68.70%-23.39M | 53.76%-52.71M | 137.15%11.28M | 71.49%-53.49M | 15.15%-74.74M | -69.99%-113.99M | -533.09%-30.37M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | --45.06M | ---- | ---- | ---- | ---- | -67.72%11.18M | --10M | --10M | --10M | --34.64M |
| Cash received from returns on investments | ---- | ---- | ---- | ---- | ---- | -89.19%69.07K | -84.49%69.07K | -20.33%69.07K | --69.07K | --638.94K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | --8.58K | 558.64%795.84K | 610.57%55.34K | --55.34K | ---- | -74.35%120.83K | -82.41%7.79K | ---- | ---- | 1,432.40%471.04K |
| Cash received relating to other investing activities | ---- | -56.96%2.13M | ---- | ---- | ---- | 15.39%4.95M | ---- | ---- | ---- | -8.14%4.29M |
| Cash inflows from investing activities | --45.06M | -82.08%2.92M | -99.45%55.34K | -99.45%55.34K | ---- | -59.24%16.32M | 199.19%10.08M | 467.12%10.07M | 1,278.15%10.07M | 752.42%40.03M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -87.80%828.36K | -53.18%31.82M | 272.43%16.6M | 262.12%16.14M | 63.31%6.79M | 161.96%67.96M | -72.38%4.46M | -31.16%4.46M | 30.44%4.16M | 17.27%25.94M |
| Cash paid to acquire investments | --55M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --40M |
| Cash paid relating to other investing activities | --72.81M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | 1,794.73%128.64M | -53.18%31.82M | 272.43%16.6M | 262.12%16.14M | 63.31%6.79M | 3.06%67.96M | -92.06%4.46M | -90.41%4.46M | 30.44%4.16M | 198.07%65.94M |
| Net cash flows from investing activities | -1,130.97%-83.57M | 44.05%-28.9M | -394.38%-16.54M | -386.60%-16.08M | -214.84%-6.79M | -99.31%-51.65M | 110.65%5.62M | 112.56%5.61M | 340.65%5.91M | -48.69%-25.91M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | -69.23%400K | ---- | ---- | ---- | -99.66%1.3M | -99.66%1.3M | -99.66%1.3M | ---- | --381.5M |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | -69.23%400K | ---- | ---- | ---- | 44.44%1.3M | 44.44%1.3M | 225.00%1.3M | ---- | --900K |
| Cash from borrowing | -74.65%29.1M | -25.96%529.67M | 24.44%410.56M | 18.30%314.04M | 3.10%114.8M | 130.96%715.34M | 30.85%329.92M | 203.43%265.47M | 66.49%111.35M | -27.84%309.72M |
| Cash received relating to other financing activities | ---- | ---- | ---- | ---- | -84.91%108.1K | ---- | ---- | ---- | -0.39%716.24K | ---- |
| Cash inflows from financing activities | -74.67%29.1M | -26.03%530.07M | 23.95%410.56M | 17.72%314.04M | 2.54%114.91M | 3.68%716.64M | -47.73%331.22M | -43.08%266.77M | -75.00%112.06M | 61.05%691.23M |
| Borrowing repayment | -27.58%40.46M | -24.37%546.13M | 66.85%371.02M | 106.77%290.51M | -25.39%55.87M | 99.40%722.15M | -10.25%222.36M | 0.10%140.5M | -31.02%74.89M | -15.26%362.16M |
| Dividend interest payment | -2.72%978.24K | -58.70%26.95M | -58.93%26.43M | -58.25%25.64M | -19.88%1.01M | -12.46%65.25M | -13.48%64.35M | -16.27%61.4M | 55.72%1.26M | -6.43%74.54M |
| Cash payments relating to other financing activities | -47.00%379.09K | -69.59%2.47M | -77.30%1.43M | -80.39%1.03M | -86.41%715.26K | -71.82%8.11M | -73.58%6.32M | -54.64%5.25M | -58.10%5.26M | 144.04%28.8M |
| Cash outflows from financing activities | -27.39%41.82M | -27.65%575.54M | 36.12%398.88M | 53.11%317.17M | -29.25%57.59M | 70.90%795.52M | -15.32%293.02M | -8.04%207.15M | -33.23%81.41M | -10.28%465.5M |
| Net cash flows from financing activities | -122.18%-12.72M | 42.34%-45.48M | -69.42%11.68M | -105.25%-3.13M | 86.96%57.32M | -134.94%-78.87M | -86.72%38.2M | -75.51%59.62M | -90.60%30.66M | 351.90%225.73M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -1,174.68%-117.54K | 165.75%254.61K | -179.80%-786.24K | -129.04%-480.98K | 114.70%10.94K | -133.04%-387.25K | -73.84%985.22K | 8.38%1.66M | -53.83%-74.39K | 148.05%1.17M |
| Net increase in cash and cash equivalents | -2,562.97%-57.91M | 149.01%58.63M | 5.58%-8.2M | -448.70%-43.09M | 97.19%-2.17M | -170.11%-119.63M | -117.03%-8.68M | -107.00%-7.85M | -130.19%-77.49M | 266.52%170.62M |
| Add:Begin period cash and cash equivalents | 31.41%245.31M | -39.06%186.68M | -39.06%186.68M | -39.06%186.68M | -39.06%186.68M | 125.75%306.31M | 125.75%306.31M | 125.75%306.31M | 125.75%306.31M | -43.03%135.69M |
| End period cash equivalent | 1.57%187.4M | 31.41%245.31M | -40.03%178.48M | -51.89%143.59M | -19.37%184.5M | -39.06%186.68M | 59.44%297.62M | 20.41%298.45M | -41.69%228.81M | 125.75%306.31M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.